Skip to content

Probiotix Health PLC - Distribution agreement

Announcement provided by

ProBiotix Health Plc · PBX

01/08/2023 07:00

Probiotix Health PLC - Distribution agreement
RNS Number : 7459H
Probiotix Health PLC
01 August 2023

ProBiotix Health plc

("ProBiotix" or the "Company")


Distribution agreement

Distribution of finished turnkey products in Australia and New Zealand


ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle lifestyle conditions such as cardiovascular disease, announces that the Company has signed an exclusive distribution agreement with Trans Chem to cover the Australian and New Zealand probiotics market.


Trans Chem is one of Australia's leading independent suppliers of innovative products and quality raw ingredients for the pharmaceutical, nutraceutical, food and beverage,veterinary and animal nutrition industries. Trans Chem's operations extend across both Australia and New Zealand. Trans Chem's customers include all the major leading pharma and nutraceutical brand owners in the region and the numerous contract manufacturers who service and support these players. They also have a strong emerging international food and beverage business. The Directors believe that Trans Chem is a strong and creditable company, winning 'Prestigious Quality Material Supplier of the Year' awarded by the Complementary Medicines Australia (CMA) in 2016, 2019 and in 2021.


Steen Andersen, CEO of ProBiotix Health plc commented: "We are delighted to have signed this agreement with Trans Chem, which will further enhance our global reach. Although our primary strategic focus is on developing the European and North American markets, we believe that there is a significant business potential in Australia & New Zealand. Both countries have a high concentration of dietary supplement companies acting as a gateway into servicing mainland China and the Southeast Asian region, which we can now capitalise on.


"Trans Chem is a leading distributor in the region and will be responsible for selling our finished turn-key product solutions based on LPLDL® into the leading brands in the regions. The finished turn-key product solutions will be manufactured through local Australian and New Zealand contract manufacturing organisations (CMO's), controlled by ProBiotix Health in cooperation with Trans Chem."    


For further information, please contact:


ProBiotix Health plc

Steen Andersen, Chief Executive

Contact via Walbrook below

Peterhouse Capital Ltd (AQSE Corporate Adviser and Broker)

Tel: 020 7469 0930

Mark Anwyl

Duncan Vasey


Walbrook PR Ltd

Anna Dunphy

Mob: 07876 741 001


Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

PBX announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal